Following allegations of sexual harassment, former head of Operation Warp Speed Moncef Slaoui has left roles at two more companies. Yesterday, Slaoui was terminated as the Galvani board of directors’ chair, GlaxoSmithKline’s board of directors announced. The same day, Vaxcyte confirmed in an SEC filing that it had axed Slaoui as its chairman of the…
GSK, Sanofi launch new study for protein-based COVID-19 vaccine
Sanofi (NYSE:SNY) and Glaxo Smith Kline (NYSE:GSK) are moving forward with their development plans of a COVID-19 vaccine. In December, the two companies announced that their vaccine development efforts had been delayed after the product failed to mount a robust immune response in older adults. The two companies believe the setback resulted from an insufficient…
GSK and CureVac team up on COVID-19 vaccine to battle viral variants
Late last year, GlaxoSmithKline (NYSE:GSK) and Sanofi (NYSE:SNY) announced that their joint COVID-19 vaccine was delayed. Now, GlaxoSmithKline is hooking up with Germany-headquartered CureVac (NSDQ:CVAC) to develop a COVID-19 vaccine that can target multiple variants of the virus simultaneously. GSK plans on spending €150 million on the project, paying the first half to CureVac initially and the latter half…
11 COVID-19 therapies you need to know
The pharmaceutical industry launched a herculean effort to battle the COVID-19 pandemic early in 2020, developing an array of vaccines and other therapeutics while also identifying existing drugs suitable for treating patients sick with severe coronavirus infections. FDA recently granted emergency authorization to two SARS-CoV-2 vaccines and several other treatments. Here are 11 of the…
Launch of Sanofi and GSK COVID-19 vaccine could be delayed until late 2021
Sanofi (NYSE:SNY) and Glaxo Smith Kline (NYSE:GSK) have confirmed a delay in their adjuvanted recombinant protein-based COVID-19 vaccine owing to an inadequate immune response in older adults in a Phase 1/2 trial. Sanofi and GSK now plan to launch a Phase 2b study in February 2021 to investigate a new vaccine formulation. If that study reaches primary endpoints,…
Medicago and GSK partner on COVID-19 vaccine trial
The Canadian biotech firm Medicago (CVE:MDG) is hooking up GlaxoSmithKline (NYSE:GSK) on a study involving 30,000 participants. The Quebec City-based Medicago had recently announced promising data concerning its plant-based vaccine candidate. Medicago’s vaccine is unique in that it uses virus-like particles that resemble the structure of the novel coronavirus but contain no genetic material from the virus. …
Sanofi, GSK offer 20M COVID-19 vaccine doses to COVAX alliance
Sanofi (NSDQ:SNY) and GSK (LON: GSK), which have teamed up to produce a COVID-19 vaccine candidate, have signaled their intent to work with the legal administrator of the COVAX Facility. The two companies have vowed to produce 200 million doses of a vaccine based on the protein subunit AS03 adjuvant. Governments, businesses and health organizations…
Sanofi, GSK seek to have an adjuvanted COVID-19 vaccine ready by late 2021
Sanofi and GSK recently announced that they have signed a letter of intent to collaborate on an adjuvanted vaccine for COVID-19 — with a goal of having the vaccine available by the second half of 2021. Sanofi is contributing its S-protein COVID-19 antigen. The company’s recombinant DNA technology produced an exact genetic match to proteins…